Program Schedule

412
In vitro Activity of Key Antimicrobial Agents Against Bacterial Isolates From Intra-abdominal (IAI) and Skin and Wound (SW) Infections: Europe 2004-2013

Session: Poster Abstract Session: Surveillance of Antimicrobial Resistance
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Background: IAI and SW infections present major challenges for hospitalized patients. Monitoring the resistance profiles expressed by the causative organisms is important. Therefore, data from the Tigecycline European Surveillance Trial (TEST) program were analyzed for the resistance patterns observed throughout Europe.

Methods: Isolates were collected and tested locally by broth microdilution according to appropriate CLSI guidelines. Results of this study were based on isolates tested from 26 European countries from 2004 2013.

Results:

Antimicrobial: Percent Susceptible: IAI/SWa

 

Organism (n): IAI/SW

TIG

AK

AMP

CFT

LEV

MER

PT

VAN

Acinetobacter spp 163/1546

na/na

66/70

na/na

28/35

50/58

53/70

45/55

na/na

Enterobacter spp 615/2478

96/96

98/98

2/4

53/65

84/89

96/98

68/78

na/na

E. coli 1122/1748

100/100

99/99

38/32

84/76

74/64

99/100

91/90

na/na

ESBL 128/311

100/100

94/96

na/na

na/na

25/22

98/99

74/73

na/na

K. pneumoniae 485/1156

97/96

96/95

2/3

75/67

79/73

95/93

78/76

na/na

ESBL 82/266

94/96

88/88

na/na

4/0

89/34

89/88

32/43

na/na

P. aeruginosa 367/2439

na/na

93/93

na/na

na/na

70/67

65/76

76/75

na/na

S. marcescens 101/861

94/96

99/98

5/4

78/83

93/93

96/99

87/94

na/na

E. faecalis 366/1067

100/100

na/na

98/99

na/na

74/8

na/na

na/na

98/99

E. faecium 381/356

100/100

na/na

21/17

na/na

17/17

na/na

na/na

91/90

S. aureus, MSSA 100/3250

100/100

na/na

na/na

na/na

95/92

na/na

na/na

100/100

S. aureus, MRSA 42/1302

100/100

na/na

na/na

na/na

12/16

na/na

na/na

100/100

S. agalactiae 27/955

100/100

100/100

100/100

100/100

100/98

100/100

na/na

100/100

A na = breakpoints not defined or non-applicable, TIG (tigecycline; FDA breakpoints), AK (amikacin), AMP (ampicillin), CFT (Ceftriaxone), MER (meropenem), LEV (levofloxacin) PT (piperacillin/tazobactam), VAN (vancomycin)

Conclusion: Against Enterobacteriaceae, including ESBL-producers, TIG, AK and MER were the most active agents; against gram-positive cocci TIG resistance was not encountered. For Acinetobacter spp. all agents demonstrated poor activity; against P. aeruginosa AK and PT were the most active agents. Given the propensity of the bacteria associated with IAI and SW infections, continued monitoring of antimicrobial activity in Europe is warranted.

 

Daryl Hoban, PhD1, Samuel Bouchillon, MD1, Robert Badal, BS1, Dan Sahm, PhD1 and Heidi Leister-Tebbe, BS2, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer Inc., Collegeville, PA

Disclosures:

D. Hoban, Pfizer: Independent Contractor, Consulting fee

S. Bouchillon, Pfizer: Independent Contractor, Consulting fee

R. Badal, Pfizer: Independent Contractor, Consulting fee

D. Sahm, Pfizer: Independent Contractor, Consulting fee

H. Leister-Tebbe, Pfizer: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek